Moonlake Immunotherapeutics (MLTX)

$46.4

-0.25

(-0.54%)

Market is closed - opens 7 PM, 15 Jul 2024

Performance

  • $45.03
    $48.69
    $46.40
    downward going graph

    2.95%

    Downside

    Day's Volatility :7.52%

    Upside

    4.7%

    downward going graph
  • $35.11
    $64.98
    $46.40
    downward going graph

    24.33%

    Downside

    52 Weeks Volatility :45.97%

    Upside

    28.59%

    downward going graph

Returns

PeriodMoonlake Immunotherapeutics
3 Months
6.32%
6 Months
-19.53%
1 Year
-7.33%
3 Years
278.78%

Highlights

Market Capitalization
2.8B
Book Value
$8.63
Earnings Per Share (EPS)
-0.72
Wall Street Target Price
73.13
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-12.09%
Return On Equity TTM
-14.99%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-61.0M
Diluted Eps TTM
-0.72
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.24
EPS Estimate Next Year
-1.97
EPS Estimate Current Quarter
-0.19
EPS Estimate Next Quarter
-0.27

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 22 Wall street analysts offering stock ratings for Moonlake Immunotherapeutics(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
17
Hold
4
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 57.61%

Current $46.40
Target $73.13

Technicals Summary

Sell

Neutral

Buy

Moonlake Immunotherapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Institutional Holdings

  • Bvf Inc

    34.59%
  • Cormorant Asset Management, LLC

    13.51%
  • FMR Inc

    6.95%
  • venBio Select Advisor LLC

    4.10%
  • Adage Capital Partners Gp LLC

    3.63%
  • T. Rowe Price Associates, Inc.

    3.40%

Corporate Announcements

  • Moonlake Immunotherapeutics Earnings

    Moonlake Immunotherapeutics’s price-to-earnings ratio stands at None

    Read More

Company Information

moonlake immunotherapeutics ag is a clinical-stage biopharmaceutical company leveraging revolutionary nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Organization
Moonlake Immunotherapeutics
Employees
50
CEO
Dr. Jorge Santos da Silva
Industry
Miscellaneous

FAQs